Wuhan General Group Recruiting in Lesotho for its Medicinal Cannabis Cultivation Facility

April 20, 2021 10:00 AM

CAPE TOWN, SA / ACCESSWIRE / April 20, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce on the occasion of ‘420 Day' or ‘Weed Day' that the company, through its local subsidiary, Tsime Pharmaceuticals and Medicinal Supplies, has started recruiting its team for...

Read more

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

April 19, 2021 4:01 PM

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or...

Read more

Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2020 Financial Results and Provide Business Update

April 19, 2021 3:00 PM

Conference Call Scheduled for Wednesday, April 21st at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / April 19, 2021 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2020 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or...

Read more

Viewpoint Molecular Targeting(TM) Presents Positive Preclinical Results of VMT01 at the 10th World Congress of Melanoma

April 19, 2021 10:00 AM

-Results demonstrated that the combination of [212Pb] VMT01 and immune checkpoint inhibitors induced synergistic anti-tumor effect and 43% complete tumor responses - - Company is launching Phase 1 imaging study of VMT01 imminently with provisional results expected in Q4 2021, followed by Phase 1/2a therapy study for the treatment of metastatic melanoma - CORALVILLE, IA / ACCESSWIRE / April 19, 2021 / Viewpoint Molecular Targeting, Inc....

Read more

Experion Announces Q1 2021 Financial Reporting Release Date and Management Presentation

April 19, 2021 8:45 AM

VANCOUVER, BC / ACCESSWIRE / April 19, 2021 / Experion Holdings Ltd. (the "Corporation" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) Canada's solution to craft cannabis supply and builder of premium cannabis brands including its sought after and popular brand Citizen Stash announced today that it will be reporting its 2021 first quarter financial results for the period ending February 28, 2021 after market close...

Read more

Biotech Medics, Inc. Now Operating Sumcoin Nodes Directly

April 16, 2021 6:35 PM

WOODLAND HILLS, CA / ACCESSWIRE / April 16, 2021 / BioTech Medics, Inc. (OTC PINK:BMCS) Announces the firm has begun operating Sumcoin Nodes directly and is exploring how to support the network with mining equipment. A significant step while BMCS continues to cooperate with FINRA for the Company's name change approval from Bio Tech Medics to BMCS Sumcoin Index Fund Inc. According to Anthony K. Miller, CEO, "We want utilize the...

Read more

Experion to Webcast Live at VirtualInvestorConferences.com on April 20, 2021

April 16, 2021 8:45 AM

VANCOUVER, BC / ACCESSWIRE / April 16, 2021 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) announced today that CEO, Mr. Jarrett Malnarich will present live at VirtualInvestorConferences.com on April 20, 2021 at 3:30 PM EST / 12:30 PM PST. Experion invites shareholders, investors, advisors, and analysts to attend the real-time, interactive investor presentation. This will be...

Read more

Stella Diagnostics Announces Completion of Corporate Name and Ticker Symbol Changes (SLDX)

April 16, 2021 8:00 AM

SALT LAKE CITY, UT / ACCESSWIRE / April 16, 2021 / Stella Diagnostics, Inc. (OTC PINK:JMDP) ("Stella" or "The Company") announced today that its corporate name change from "JMP Properties, Inc." to "Stella Diagnostics, Inc." became effective on April 16, 2021. In connection with the name change, the Company's common stock will begin trading on the OTC Markets under the ticker symbol "SLDX" at...

Read more

Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants

April 15, 2021 4:05 PM

KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of a new Chief Financial Officer and the issuance of share purchase warrants to third party consultants. Lexaria is pleased to announce that effective April 15, 2021, Gregory Downey will be assuming the role of Chief...

Read more

MJ Biotech Inc. Ships Its First Purchase Order to Namibia Africa

April 15, 2021 7:30 AM

CHEYENNE, WY / ACCESSWIRE / April 15, 2021 / MJ Biotech Inc. (OTC PINK:MJTV), has shipped its first Purchase Order of its COVID 19 Rapid Test Kit to Namibia, Africa. The Rapid Test Kit is a nasal swab test that produces test results in 10 minutes. This purchase order of 120 units is designed to facilitate an efficient method of delivery as the Purchase Orders increase in order quantity. This is an exciting time for the Company and for...

Read more

Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis

April 15, 2021 2:00 AM

Tetra strengthens its intellectual property portfolio Approximately 12% of women may have early symptoms of Interstitial Cystitis OTTAWA, ON / ACCESSWIRE / April 15, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces the granting of a new patent from the United States Patent and Trademark...

Read more

Medspresso(TM) Partners with CNC Products for Online Listing and CSR Activities

April 14, 2021 11:15 AM

CAPE TOWN, SA / ACCESSWIRE / April 14, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: The company is pleased to announce its brand Medspresso™ has partnered with CNC, the preferred food supplier to top chefs, restaurants, and home cooks all...

Read more

BioLargo Inc. to Present at Benzinga Cleantech Small Cap Conference on April 22nd at 11:20am EST

April 14, 2021 8:30 AM

WESTMINSTER, CA / ACCESSWIRE / April 14, 2021 / BioLargo, Inc. (OTCQB:BLGO), developer of sustainable clean technologies and a full-service environmental engineering company will be presenting at the Benzinga Cleantech Small Cap Conference on Earth Day, April 22, 2021, at 11:20am EST. The company invites its shareholders and all interested parties to learn more about BioLargo, cleantech, and environmental remediation investment...

Read more

Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology

April 14, 2021 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) On April 7, 2021 Oncology Pharma, Inc. (the "Company") reported that it had been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize pancreatic cancer treatments utilizing Regen's proprietary intellectual property pertaining to mRNA. A Spokesperson for the Company, today expanded on the...

Read more

Pressure BioSciences Finalizes Plan to Acquire Global Eco-Friendly Agrochemical Supplier

April 14, 2021 7:31 AM

Company Expects Acquisition to be Accretive with Sustained Profitable Revenue Growth, Leveraging Market-Changing Synergy from PBI's Ultra Shear Technology Nanoemulsions Platform SOUTH EASTON, MA / ACCESSWIRE / April 14, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology...

Read more

Enveric Biosciences to Participate in the Planet MicroCap Showcase on April 21st

April 14, 2021 7:30 AM

NAPLES, FL / ACCESSWIRE / April 14, 2021 / Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David Johnson, Chairman and Chief Executive Officer, will present at the Planet MicroCap Showcase to be held virtually on Wednesday, April 21, 2021 at 9:00 a.m. ET. To access...

Read more

Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network

April 14, 2021 7:00 AM

DehydraTECHTM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced that its corporate client Amari Corp.'s "Everyday Calm" CBD product was named a Top CBD Product Pick by New Hope Network, host of the industry-leading...

Read more

Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada

April 14, 2021 2:00 AM

REDUVO would have Canada's only Drug Identification Number for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / April 14, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have advanced the REDUVO soft gel capsules...

Read more

Viewpoint Molecular Targeting(TM) Presents Positive Preclinical Results of VMT01 at the 2021 American Association for Cancer (AACR) Annual Meeting

April 13, 2021 10:00 AM

- Preclinical study evaluated melanocortin 1 receptor (MC1R) as a potential target for MC1R-targeted therapies for metastatic melanoma, the lead target of VMT01 - - Results indicate that MC1R-targeted therapies, such as VMT01, are a promising alternative to current therapies for metastatic melanoma - - Company is launching Phase 1 imaging study of VMT01 imminently with provisional results expected in Q4 2021, followed by Phase 1/2a therapy...

Read more

Philogen Announces Publication of Best-in-Class FAP-Targeting Small Molecule Ligand (OncoFAP) in PNAS

April 12, 2021 3:00 PM

(i) Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs - (ii) OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer SIENA, ITALY / ACCESSWIRE / April 12, 2021 / Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to...

Read more